Analysts believe that if approved, VX-548 could generate ove...
Analysts believe that if approved, VX-548 could generate over $5B in annual sales for Vertex. Despite the trials not showing superiority over opioids, the safety and addiction advantage of the drug is seen as a significant benefit.
![](https://pubimg-10000538.picsh.myqcloud.com/2022050900000320f7ca37c56bf.jpg)
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment